Psychedelic Medicine
March 10, 2026
Amy Lehrner, Miryam Sperka, Lauren Lepow et al.
1 citation
There is growing interest in incorporating MDMA (3,4-Methylenedioxymethamphetamine) into structured, evidence-based cognitive-behavioral treatment protocols for post-traumatic stress disorder. Yet this risks overlooking the distinctive qualities of MDMA-assisted therapy, which has already demonstrated strong clinical effects, high response rates, and low dropout using a principle-guided,...
Psychedelics
January 8, 2026
Rachel Yehuda, Amy Lehrner, Miryam Sperka et al.
2 citations
The original MAPS manual for MDMA-assisted therapy (MDMA-AT) opened a therapeutic frontier for PTSD. However, it drew critique for concepts—such as “inner healing intelligence” – that originated in transpersonal traditions rather than academic or empirically grounded clinical models. While many patients found the therapies helpful, these constructs were difficult to interpret and standardize....
Journal of Traumatic Stress
May 7, 2025
Mark Creamer, Richard Bryant, Amy Lehrner et al.
1 citation
This paper is an edited transcript of a plenary panel held at the 2024 Annual Meeting of the International Society for Traumatic Stress Studies (ISTSS) in Boston, Massachusetts, United States. The panel comprised Drs. Mark Creamer (moderator), Richard Bryant (convenor), Amy Lehrner, Barbara O. Rothbaum, Joseph I. Ruzek, and Paula P. Schnurr. Bringing together clinicians and researchers with a...
Journal of Psychoactive Drugs
February 7, 2025
Amy Lehrner, Heather Jackson, David S. Mathai et al.
11 citations
The classic psychedelic psilocybin has attracted special interest across clinical and non-clinical settings as a potential tool for mental health. Despite increasing attention to challenging psychedelic experiences, few studies have explored the relevance of shame-related processes with psychedelic use. This prospective, longitudinal study involved sequential, automated, web-based surveys that...
JAMA
August 31, 2023
Rachel Yehuda, Amy Lehrner
33 citations
An increasing number of clinicians and researchers have become interested in the potential of psychedelic drugs for the treatment of mental health disorders, including depression, anxiety, posttraumatic stress disorder, eating disorders, and addictions.1,2